Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
4 hedge funds and large institutions have $150K invested in Argos Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
75% less funds holding
Funds holding: 16 → 4 (-12)
82% less capital invested
Capital invested by funds: $844K → $150K (-$694K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$27.1K |
| 2 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$1.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$25K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PI
1
Pharmstandard International
Luxembourg
| $136K | – | – | – |
|
|
WS
2
Wedbush Securities
Los Angeles,
California
| $13K | +$27.1K | +35,000 | +81% |
|
|
MAM
3
Meeder Asset Management
Dublin,
Ohio
| $936 | +$1.67K | +2,157 | +61% |
|
|
TSS
4
Two Sigma Securities
New York
| – | -$25K | -27,911 | Closed |
|
|
5
Balyasny Asset Management
Chicago,
Illinois
| – | -$14K | -15,350 | Closed |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$10K | -10,724 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$8K | -9,354 | Closed |
|
|
AG
8
Advisor Group
Phoenix,
Arizona
| – | -$1K | -575 | Closed |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| – | -$45 | -50 | Closed |
|
ARGS Hedge Fund Activity: Q2 2018 in Review
4 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q2 2018, worth a combined $150K — down 82% from $844K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARGS and 0 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Wedbush Securities, adding an estimated $27.1K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $25K sold.
- 4 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q2 2018, down from 16 in Q1 2018.
- Funds reported $150K of Argos Therapeutics, Inc. stock for Q2 2018, down 82% quarter-over-quarter.
- 0 funds opened new Argos Therapeutics, Inc. positions in Q2 2018 and 12 closed out, a net change of -12 holders.
- The largest Argos Therapeutics, Inc. buyer in Q2 2018 was Wedbush Securities, an estimated $27.1K added.
- The largest Argos Therapeutics, Inc. seller in Q2 2018 was Two Sigma Securities, an estimated $25K sold.
Based on aggregated 13F filings for Q2 2018.